Related Experiment Video
Updated: Feb 16, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
p300-mediated acetylation of KCNN4 drives enzalutamide resistance in prostate cancer
Weiqiang Song1, Jiankun Zhang1, Zekun Xin1
1Department of Urology, Hebei Petrochina Central Hospital, Xinkai Road NO.51, Langfang City, Hebei Province, 065000, China.
Abstract:
Enzalutamide resistance remains a critical obstacle in the treatment of castration-resistant prostate cancer (CRPC), with potassium calcium-activated channel subfamily N member 4 (KCNN4) emerging as a key mediator of therapeutic failure. Here, we demonstrate that KCNN4 is significantly upregulated in enzalutamide-resistant PCa cells and clinical tissues, correlating with poor prognosis. Mechanistically, p300, a histone acetyltransferase, directly binds to KCNN4 and mediates its acetylation at lysine 16, which competitively inhibits ubiquitination-mediated degradation, thereby stabilizing KCNN4 protein. Notably, p300 inhibition disrupts KCNN4 acetylation, restores its proteasomal degradation, and resensitizes resistant cells to enzalutamide both in vitro and in vivo. Moreover, KCNN4 knockdown suppresses tumor growth and synergizes with enzalutamide in xenograft models, underscoring the therapeutic potential of targeting the p300-KCNN4 axis. Collectively, our findings reveal a previously unrecognized epigenetic regulatory mechanism coupling p300-mediated acetylation to potassium channel stability, providing a promising therapeutic strategy to overcome chemoresistance in advanced prostate cancer.
Insights
Targeting the p300-KCNN4 pathway can overcome enzalutamide resistance in prostate cancer. Inhibiting p300 stabilizes KCNN4, resensitizing resistant cells to treatment and suppressing tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Enzalutamide resistance is a major challenge in castration-resistant prostate cancer (CRPC).
- Potassium calcium-activated channel subfamily N member 4 (KCNN4) is implicated in therapeutic failure.
- Understanding resistance mechanisms is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of KCNN4 in enzalutamide resistance.
- To elucidate the regulatory mechanism of KCNN4 stability.
- To explore therapeutic strategies targeting the p300-KCNN4 axis.
Main Methods:
- Analysis of KCNN4 expression in enzalutamide-resistant prostate cancer (PCa) cells and clinical tissues.
- Investigation of the interaction between p300 and KCNN4 using biochemical assays.
- Assessment of the effects of p300 inhibition on KCNN4 acetylation, degradation, and enzalutamide sensitivity in vitro and in vivo.
- Evaluation of KCNN4 knockdown in combination with enzalutamide in xenograft models.
Main Results:
- KCNN4 is upregulated in resistant PCa, correlating with poor prognosis.
- p300 acetylates KCNN4 at lysine 16, inhibiting its ubiquitination and degradation, thus stabilizing the protein.
- p300 inhibition reduces KCNN4 acetylation, promotes its degradation, and resensitizes resistant cells to enzalutamide.
- KCNN4 knockdown suppresses tumor growth and synergizes with enzalutamide.
Conclusions:
- A novel epigenetic mechanism links p300-mediated acetylation to KCNN4 stability.
- Targeting the p300-KCNN4 axis offers a promising strategy to overcome enzalutamide resistance in advanced prostate cancer.
- This approach could improve therapeutic outcomes for CRPC patients.
Related Concept Videos
Treatment Resistant Cancers
Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Resistivity
Resistance

